HKMPY - Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
https://www.hikma.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 8,800
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Engineer Said Samih Taleb Darwazah | Exec. Chairman & CEO | 2.97M | N/A | 1957 |
| Mr. Mazen Samih Taleb Darwazah | Exec. Vice Chairman & Pres of MENA | 1.95M | N/A | 1958 |
| Mr. Khalid Waleed Hosny Al Nabilsi | Chief Financial Officer | N/A | N/A | 1972 |
| Mr. Guy Featherstone | Associate Director of Investor Relations | N/A | N/A | N/A |
| Mr. Hussein Arkhagha | Company Sec. & Chief Counsel | N/A | N/A | N/A |
| Mr. Bassam Wael Rushdi Kanaan CFA, CPA | Exec. VP of Corp. Devel. and M&A | N/A | N/A | 1965 |
| Ms. Susan Ringdal | Exec. VP of Strategic Planning & Global Affairs | N/A | N/A | N/A |
| Ms. Majda Labadi | Exec. VP of Organisational Devel. | N/A | N/A | N/A |
| Mr. Riad Mishlawi | Pres of Injectables | N/A | N/A | N/A |
| Mr. Brian Hoffmann | Pres of Generics | N/A | N/A | N/A |
Description
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.
Corporate governance
Hikma Pharmaceuticals PLC’s ISS governance QualityScore as of 1 June 2023 is 3. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 1; Compensation: 3.
